Entries |
Document | Title | Date |
20080261254 | Procedure for the determination of the reaction lag phase in an analyte-dependent reaction - The invention is in the field of analytical technique and relates to an improved procedure for determining the concentration or activity of an analyte, an analyte-dependent detection reaction being set in motion and the reaction kinetics determined being evaluated. The procedure makes possible an individual determination of the lag phase of the reaction kinetics for each measurement. | 10-23-2008 |
20080268483 | Methods for a Global Assay of Coagulation and Fibrinolysis - The present disclosure concerns methods of analyzing both clot formation and fibrinolysis in a sample, preferably simultaneously. In certain embodiments, the methods may comprise adding a small amount of at least one activator of coagulation and at least one activator of fibrinolysis to a sample and analyzing the sample for kinetic parameters related to clot formation and fibrinolysis. In another embodiment, the methods may comprise analyzing a sample from a subject for clot formation and fibrinolysis and detecting or diagnosing a disease or condition and/or applying information obtained from analyzing clot formation and fibrinolysis to determine a treatment for a medical condition of the subject. | 10-30-2008 |
20080268484 | Screening Method for a Growth Inhibitor or Promoter of a Vascular Smooth Muscle Cell - It was found that TAT which has not been known biological activity has a role as a new blood vessel smooth muscle proliferation factor, and then a screening method vascular of an inhibitor or promoter of a smooth muscle cell growth with TAT is established. | 10-30-2008 |
20080318259 | Hematocrit and Analyte Concentration Determination - A method to determine an analyte concentration of an anticoagulated plasma by performing at least two different measurements on a mixture of a blood sample corresponding to said anticoagulant plasma and of liquid reagent is described. The method comprises a) mixing a volume of said blood sample with a five-fold, or more, volume of said liquid reagent, b) performing said at least two measurements on said mixture, at least one of which correlates with the hematocrit of said blood sample and at least one of which correlates with said analyte concentration, and c) computing the results from the measurements when the volumes in a) are precise and accurate or when the hematocrit of said blood sample in b) is known to determine said analyte concentration of said anticoagulated plasma. In addition, a measurement and determination device for performing measurements on blood, anticoagulated blood and/or anticoagulated plasma samples, and an equipment kit are described. | 12-25-2008 |
20080318260 | Methods and Apparatus for Measuring Blood Coagulation - The present invention provides apparatus and methods for performing assays for determining the time required for a sample of blood to coagulate. The apparatus comprises reaction chambers coated with one or more clotting agent. A drop of blood or equivalent is placed at the sample application port, diluted, and contacted with the clotting agents in the reaction chambers. The diluted blood sample can be moved back and forth through the reaction chambers until blood clots. The blood clotting process forms fibrin stands that prevent the flow of the blood sample in the reaction chambers. The clotting time is the total time from the sample entering the reaction chambers to the time at which the waveform in the reaction chambers change, or the motion or flow of the sample ceases, and can be measured by turbidity. | 12-25-2008 |
20090004681 | PLATELET AGGREGATION MEASURING METHOD AND PLATELET AGGREGATION MEASURING APPARATUS - A platelet aggregation measuring method comprising: preparing a measurement sample which contains a sample and a reagent which includes a platelet activator; mixing the measurement sample at a first speed; mixing the measurement sample at a second speed which is greater than the first speed after mixing the sample at the first speed; obtaining optical information from the measurement sample while mixing the measurement sample at the second speed; and analyzing aggregation of platelets in the sample based on the optical information is disclosed. A platelet aggregation measuring apparatus is also disclosed. | 01-01-2009 |
20090011447 | QUANTIFICATION OF VITELLOGENIN - The present invention is directed to a simple method for absolute quantification of plasma vitellogenin from two or more different fish species such as Rainbow trout and Atlantic salmon, or Atlantic cod and haddock. In the case of Rainbow trout and Atlantic salmon, plasma samples obtained from control and β-estradiol induced fish were digested with trypsin. A characteristic ‘signature peptide’ was selected and analyzed by high performance liquid chromatography coupled to an electrospray quadrupole-time-of-flight tandem mass spectrometer, using a deuterated homologue peptide as an internal standard. The hybrid tandem mass spectrometer was operated in a ‘pseudo’ selected reaction monitoring mode by which three diagnostic product ions were monitored for identification and quantification purposes. The reproducibility (coefficient of variation ˜5%) and sensitivity (limit of quantification of 0.009 mg/mL) achieved by this simple assay allow it to be considered as an alternative to immunological assays. In the case of Atlantic cod and haddock, the amino acid sequence of the vitellogenin protein has not yet been determined, but, the Atlantic cod vitellogenin has been characterized using a ‘bottom-up’ mass spectrometric approach. Vitellogenin synthesis was induced ‘in vivo’ with β-Estradiol, and subjected to trypsin digestion for characterization by matrix-assisted laser desorption/ionization-Quadrupole-Time-of-flight tandem mass spectrometry. A peptide mass fingerprint was obtained and ‘de novo’ sequencing of the most abundant tryptic peptides was performed by low energy collision induced dissociation-tandem mass spectrometry. Thus, the sequences of various tryptic peptides have been elucidated. It has also been determined that Atlantic cod vitellogenin shares a series of common peptides with the two different known vitellogenin sequences of Haddock, a closely related species. There are also disclosed novel isolated signature peptides, namely Thr-Tyr-Phe-Ala-Gly-Ala-Ala-Ala-Asp-Val-Leu-Glu-Val-Gly-Val-Arg, Asp Leu Gly Leu Ala Tyr Thr Glu Lys, Phe Phe Gly Gln Glu Ile Ala Asn Ile Asp Lys, Glu Ile Val Leu Leu Gly Tyr Gly Thr Met Ile Ser Lys and Tyr Glu Ser Phe Ala Val Ala Arg. | 01-08-2009 |
20090011448 | PRETREATMENT AGENT FOR LIMULUS TEST - A pretreatment agent for a sample to be subjected to Limulus assay comprising an alkali metal sulfate and/or an alkaline earth metal sulfate wherein the sulfate(s) has a final concentration of 20 mM or more when the sulfate(s) is allowed to contact with the sample, or an alkali metal halide and/or an alkaline earth metal halide wherein the halide(s) has a final concentration of from 0.4 M to 1.2 M or less when the halide(s) is allowed to contact with the sample, or a kit for Limulus assay reagent comprising thereof as a composing article. | 01-08-2009 |
20090061468 | REAGENT AND METHOD FOR MEASURING COAGULATION TIME OF BLOOD SAMPLE - A reagent kit for measuring coagulation time is described herein. This reagent comprises calcium chelator which interferes with the reaction between calcium and substance other than a coagulation factor in a blood sample, and which substantially does not interfere with coagulation reaction. | 03-05-2009 |
20090087870 | HEMATOLOGICAL ASSAY AND KIT - The present invention is directed to a kit and a method for a fast and direct determination of the coagulation potential of a sample of blood or plasma utilising a thrombin substrate. The kit comprises at least one activator of the plasmatic coagulation system and a thrombin substrate with a K | 04-02-2009 |
20090098585 | REAGENT KIT FOR DETECTING LUPUS ANTICOAGULANT - A reagent kit capable of distinguishing between a blood sample containing lupus anticoagulant and blood samples from individuals having other anticoagulant diseases is disclosed. The reagent kit comprises two coagulation time reagents containing phosphatidylserine in a different phosphatidylserine content ratio to the total content of phospholipids from each other, threreby giving different coagulation times with use of corresponding coagulation time reagent. | 04-16-2009 |
20090104637 | Method and Apparatus for Assaying Blood Clotting - This invention provides an apparatus for assaying clotting activity. The apparatus includes an inlet for a blood fluid and two or more patches of material in the vessel. The material is capable of initiating a clotting pathway in a blood fluid. This invention also provides an apparatus for measuring clot propagation, which includes a region with material capable of initiating a clotting pathway, and a region where the clot propagation is monitored. Also provided are methods for assaying clotting activity, assaying the integrity of a blood clotting pathway, assaying the effect of a substance on the integrity of a blood clotting pathway, monitoring clot propagation, and preventing clot propagation from one vessel to another. | 04-23-2009 |
20090136975 | Non-desensitizing mutant of the transient receptor potential TRPM5 ion channel - There exists a need in the art for high throughput screening assays that can identify compounds that specifically modulate the activity of fast-acting ion channels, such as TRPM5. Current methods, especially electrophysiological, suffer from a lack of sensitivity, rapid signal loss, low throughput, and are labor intensive. The claimed methods and compositions provide electrophysiology methods that allow prolonged sample testing and fluorescent assays with an optical readout that gives rapid readout of the results, has a high signal to noise background ratio, are easy to use, can be modified for automation and miniaturization, and provide verification that a compound specifically modulates TRPM5. | 05-28-2009 |
20090148873 | Apparatus and method to measure platelet contractility - An apparatus and method for measuring blood platelet contractility, hereinafter called a “retractometer” is disclosed. Also disclosed is a system apparatus and method for automatically measuring platelet contractility in a plurality of samples, having an array of retractometer units and an electronic solenoid valve controller to fully automate screening in clinical and research situations and.save costs in labor. | 06-11-2009 |
20090162880 | THROMBOPLASTIN REAGENT WITH LONG-TERM STABILITY - The present invention is in the area of coagulation analysis and relates to a reagent which is based on recombinant or native tissue factor and phospholipids and which can be stabilized by adding a polyphenol. | 06-25-2009 |
20090176261 | METHOD OF DETERMINING THE POINT AT WHICH COAGULATING BLOOD FORMS A CLOT - The present invention is concerned with a method and apparatus for determining the instant at which coagulating blood forms a clot—the primary function of a clot being to act as a hemostatic plug at the site of a lesion in the circulatory system. The method comprises applying a harmonically time-varying stress and strain of controlled amplitude and frequency to the blood using a rheometer and through the use of the Chambon-Winter Gel Equation, the method is capable of determining the gel point which precedes the clotting time indicated by a thromboelastograph. | 07-09-2009 |
20090191577 | METHOD AND MEDIUM FOR DETECTING THE PRESENCE OR ABSENCE OF STAPHYLOCOCCUS AUREUS IN A TEST SAMPLE - A presence/absence test for | 07-30-2009 |
20090208988 | Protocol and Apparatus for Determining Heparin-induced Thrombocytopenia - A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood hemostasis parameters. The measured blood hemostasis parameters permit determination of heparin-induced thrombocytopenia II complex (HiT II). | 08-20-2009 |
20090221011 | Coagulation test system - A test element for the determination of coagulation in a plasma or whole blood sample having a first surface ( | 09-03-2009 |
20090221012 | Method for Detecting Procoagulant Phospholipid - The present invention relates to a method for determining the amount of procoagulant phospholipid in a sample, said method comprising steps (i) to (iii) performed in the following order: (i) forming an admixture of the sample and a substrate plasma which has been rendered free or substantially free of procoagulant phospholipid sufficient to at least reduce the capacity of the substrate plasma to coagulate, wherein said substrate plasma has been rendered free or substantially free of procoagulant phospholipid by treatment with a phospholipase; (ii) contacting the admixture with a reagent for activating coagulation of plasma in conditions were procoagulant phospholipids is the rate limiting component of the mixture; and (iii) determining the clotting time if the admixture. | 09-03-2009 |
20090298103 | Predicting hemostatic risk; dependence on plasma composition - Featured are methods for assessing hemostatic risk including the risk for ACS. Such methods include acquiring blood/plasma composition based on a biological sample obtained from a subject, determining parameters associated with blood clotting, simulating in silico blood clotting using the determined parameters and comparing the results of such simulation to a reference and to determine the hemostatic risk from said comparing. In further embodiments, such methods further include selecting a treatment regime or protocol based on the results of such comparing. In yet further embodiments, such methods further include assessing the efficacy of medicants, drugs and the like of a given treatment protocol such as by simulating in silico the application of such medicants, drugs and the like. | 12-03-2009 |
20090305315 | HUBBED DUAL CANNULA DEVICE FOR CLOSED CONTAINER SAMPLING SYSTEMS - The present invention provides a hubbed dual cannula device for extracting a fluid sample from a closed container. The device comprises a housing hub, two substantially parallel needles, a venting valve and a hydrophobic membrane, and may be used effectively to extract a fluid sample from a sealed container, such as a vacuum tube, without damaging the cellular components or activating platelets in the fluid sample. Also provided are methods for using the disclosed device to extract a fluid sample from a closed container and kits for measuring platelet aggregation using such a device. | 12-10-2009 |
20090311730 | Measuring thrombin activity in whole blood - The invention relates to a method for in vitro determining thrombin activity in a sample wherein the sample is a blood sample and thrombin generation is measured by the steps of: —contacting a layer of said sample with a fluorogenic substrate of thrombin, wherein said layer has a thickness within a range of 0.05 to 5 mm and a surface within a range of 10 to 500 mm2; —allowing thrombin to generate in said sample; —measuring the fluorescence emitted from the surface of the layer, by the fluorescent group released from the fluorogenic substrate as a result of enzymatic action of generated thrombin on said fluorogenic substrate. | 12-17-2009 |
20100009396 | METHOD FOR MEASURING THE CONCENTRATION OF ACTIVATED FACTOR VII (FVIIA) IN A SAMPLE - The present application concerns a method for the in vitro or ex-vivo measurement of the FVIIa concentration of a sample, comprising the steps consisting of:
| 01-14-2010 |
20100015649 | BIOSENSOR - The present application provides apparatus ( | 01-21-2010 |
20100041081 | Protocol For Risk Stratification of Ischemic Events and Optimized Individualized Treatment - A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood hemostasis parameters. The measured blood hemostasis parameters permit preparation of an individualized assessment of ischemic event risk and individualized treatment of a subject. | 02-18-2010 |
20100047834 | METHOD FOR STABILIZING ALPHA-THROMBIN IN THROMBIN-CONTAINING SOLUTION - To provide a method for stabilizing unstable α-thrombin in a thrombin-containing solution, a solution containing stabilized α-thrombin, and a liquid fibrinogen assay reagent containing the solution. The method for stabilizing α-thrombin in a thrombin-containing solution, which includes adjusting the percentage of α-thrombin to 70% or more with respect to the amount of total thrombin in the thrombin-containing solution. | 02-25-2010 |
20100086953 | Blood Coagulation Assays - The invention relates to methods for determining the activity of a proteolytic coagulation factor of the blood coagulation cascade in a body fluid such as whole blood or plasma. A combination is provided in a reaction mixture. The combination comprises the sample and an activation agent for activating a proteolytic coagulation factor of the blood coagulation cascade or for activating the blood coagulation cascade. The effect of the activating on a reagent system comprising a cleavable moiety is evaluated. The cleavable moiety is or becomes bound to a chemiluminescent agent or a sensitizer agent or both. The chemiluminescent agent and the sensitizer agent are related in that, when in close proximity, energization of the sensitizer agent results in energization of the chemiluminescent agent. The effect of the activating is related to the activity of a proteolytic coagulation factor of the blood coagulation cascade wherein the effect is the extent of cleavage of the cleavable moiety. | 04-08-2010 |
20100105091 | Method for Measuring the Concentration of Transient Proteolytic Activity in Composite Biological Media Containing Cells - A method is provided for determining in real time the course of thrombin activity in a sample of clotting blood or plasma as it appears in and disappears from the sample which comprises adding a signal substrate to said sample, said signal substrate causing a detectable signal related to the amount of conversion product formed upon reaction by the generated proteolytic activity, monitoring the signal development in time in said sample to provide a curve, and mixing said sample frequently so that clot formation occurs in a dense manner such that the majority of the sample remains fluid and that cell precipitation is inhibited, wherein said monitoring and mixing steps are repeated and performed in an alternate way. | 04-29-2010 |
20100129841 | DETECTION OF A BLOOD COAGULATION ACTIVITY MARKER IN A BODY FLUID SAMPLE - The invention relates to a method for detecting in a body fluid sample at least one blood coagulation activity marker that reflects the blood coagulation activity of an individual. By correlating the amount or concentration of the blood coagulation activity marker present e.g. in a urine sample, it is possible to monitor the blood coagulation activity of a patient following surgery without having to obtain a blood sample from said patient. | 05-27-2010 |
20100184106 | Thrombin Substrate and Assay for Determining the Level of Bioactive Thrombin in a Sample - Substrates for thrombin and assays for determining the level of bioactive thrombin in a sample are disclosed, wherein the substrate has the general formula: A-X-Z-A′ wherein one of either A or A′ comprises a luminescent chelate and the other one of A or A′ comprises a first partner of a binding pair, X forms a tri- or tetra-peptide, and Z comprises a linker. | 07-22-2010 |
20100190193 | DIAGNOSTIC COMPOSITION AND ITS USE IN THE DETERMINATION OF COAGULATION CHARACTERISTICS OF A TEST LIQUID - The present invention is directed to a diagnostic composition for use in the viscoelastic analysis of a test liquid, and to a container ( | 07-29-2010 |
20100203562 | PLASMA FILTRATION - The invention relates to a process for preparing blood plasma for determining one or more blood parameters, in particular coagulation parameters. In order to improve the measurement, the blood plasma is sucked through a filter by means of reduced pressure. | 08-12-2010 |
20100216174 | METHOD OF EVALUATING THROMBOGENIC MICROPARTICLES - A method and a kit are disclosed for evaluating thrombogenic microparticles (MP). The principle is based on the evaluation of thrombin generation in platelet poor plasma (PPP) and in plasma made microparticle free (MPFP) by centrifugation or filtration. The difference in thrombin generation between PPP and MPFP correlates with number and activity of thrombogenic microparticles. Evaluating thrombin generation of different standardized amounts of MPs in standard MPFP allows to calculate the number of thrombogenic MP from the difference in thrombin generation between PPP and MPFP. | 08-26-2010 |
20100227346 | Activation Mixture - The present invention relates to an activation mixture comprising factor-deficient substrate plasma, an activator, and a phospholipid. The present invention also relates to a method for preparing, and the use of, an activation mixture. The present invention further relates to an assay method for determining the amount of blood coagulation factor in a test sample and a kit for performing the assay method described therein. | 09-09-2010 |
20100227347 | DIAGNOSTIC TEST CALIBRATION ADJUSTMENT METHOD - A method is provided for adjusting either the signal measured or activity calculated by an instrument or a predefined calibration curve for a medical diagnostic test, performed on an instrument with pre-calibrated reagents. A calibration adjuster for a blood clotting diagnostic test is further provided. | 09-09-2010 |
20100248278 | METHOD AND A DEVICE FOR CHARACTERIZING THE COAGULATION OR SEDIMENTATION DYNAMICS OF A FLUID SUCH AS BLOOD OR BLOOD PLASMA - A method of characterizing the coagulation or sedimentation dynamics of a fluid such as whole blood, a blood fraction, or blood plasma, the method comprising: illuminating a sample of said fluid with a beam of coherent light; acquiring a time series of images of a speckle pattern generated by interaction between said sample and said spatially coherent light beam; and processing said time series of images; wherein said processing step includes calculating a function representative of the variation in said speckle pattern between two or more images of the series. The invention also provides a device for implementing such a method. | 09-30-2010 |
20100261211 | METHOD AND APPARATUS FOR MONITORING SPATIAL FIBRIN CLOT FORMATION - The present invention relates to a method, a special designed cuvette ( | 10-14-2010 |
20100267065 | APPARATUS AND METHODS FOR ANALYZING FLUID VARIABLES - Methods and devices for analyzing fluid variables such as viscosity, surface tension, analyte concentration, the presence of particulates or aggregates are provided. The devices analyze fluid variables by measuring cessation of fluid flow through the medium or a change in flow rate due to an inherent property of the fluid variable, or due to a modification of the fluid variable as the fluid migrates through the medium. One lateral flow device provided analyzes a fluid variable in a sample by measuring relative rates of capillary flow down two or more converging arms of a common element of porous media, such as filter paper, in which at least one of the arms has been modified by the addition of flow-modifying agents which affect the flow rate in response to the concentration of the analyte. The fluid fronts will converge at a position determined by their relative flow rates, which is thus indicative of a fluid variable, such as analyte concentration, in the sample fluid. Another lateral flow device provided herein analyzes fluid variables in a sample by measuring relative rates of capillary flow down two or more arms of a common element of porous media, such as filter paper, in which at least one of the arms has been modified by the addition of flow-modifying agents which affect the flow rate in response to the concentration of the analyte. The relative distance at completion of the fluid fronts from the sample introduction point is determined by their relative flow rates, which is thus indicative of the fluid variable, such as concentration of analyte, in the sample fluid. Yet another lateral flow device provided herein qualitatively measures fluid variables in a sample by detecting changes in the rate of the capillary flow of the sample fluid along a path through an element of porous media, or through multiple elements of porous media which are in serial contact with each other, in which the sample and/or the fluid path has been modified by the addition of flow-modifying agents which cause flow to stop in the presence of the fluid variable, such as a particular concentration of analyte. | 10-21-2010 |
20100267066 | MICROCHIP AND BLOOD MONITORING DEVICE - A microchip comprising therein a first channel which allows inflow of a first liquid selected from whole blood, platelet-rich plasma and a drug-treated liquid thereof, a second channel connected to the first channel, which allows inflow of a second liquid containing an agent that is reactive with the first liquid, and a merged channel extended from the connection portion of the first channel with the second channel, wherein, in the merged channel, a stirring section having a stirring bar for mixing the first liquid with the second liquid is provided; and a blood monitoring device using the same. | 10-21-2010 |
20100291603 | ASSESSING BLOOD COMPONENTS - This document relates to methods and materials involved in assessing blood components (e.g., assessing von Willebrand factor activity or platelet activity) in mammals. For example, methods and materials involved in using labeled platelets to assess von Willebrand factor activity in a sample (e.g., plasma) from a mammal (e.g., a human) are provided. | 11-18-2010 |
20100330597 | Heat-Treated Limulus Amebocyte Lysates - The application provides heat-treated | 12-30-2010 |
20110014640 | BLOOD COAGULATION ANALYZER, BLOOD COAGULATION ANALYSIS METHOD, AND COMPUTER PROGRAM PRODUCT - A blood coagulation analyzer is provided by which, while the measurement using reagent for measuring a Fbg (fibrinogen concentration) is being minimized, the result of a measurement such as a PT measurement can be used to accurately acquire a fibrinogen concentration. The blood coagulation analyzer ( | 01-20-2011 |
20110020850 | METHOD OF DETERMINING ENZYMATIC ACTIVITY IN BIOLOGICAL MEDIA - A reliable, fast and convenient method is provided to determine the change in concentration of enzyme in time in a biological medium in the presence of a signal substrate that corrects for substrate consumption, color-dependency of the signal and non-linearity between the concentration of the leaving group of the signal substrate and the amount of signal. The method comprises the measurement of a calibrator curve in a suitable medium, such as a buffer, to determine the characteristics of the measured curve. These characteristics will then allow to obtain this whole curve or a sufficient part thereof again through a mathematical procedure based on a single-point measurement in a sample of a medium in which the enzyme generation takes place. This has the great advantage that there is no need to measure the whole calibrator curve in each individual medium, since a single-point measurement is adequate. | 01-27-2011 |
20110039285 | MICROFLUIDIC DEVICE AND METHOD FOR FLUID CLOTTING TIME DETERMINATION - A microfluidic passive device and a method for determining clotting time are described, of a fluid medium such as blood, of low production cost which can therefore be disposable. When optimised to determine blood clotting time, it requires a minimal whole blood sample (<5 μL) and it is particularly suited to INR or PT determination, which can be used autonomously by patient without venipuncture. Monitoring, and processing means to interpret the results are comprised in an external coagulometer device. A production method for the manufacture of the microfluidic device is also provided. | 02-17-2011 |
20110045512 | TIME-COURSE MEASUREMENT OF ENZYMATIC ACTIVITY CORRECTED FOR IMPACTS OF DISTURBANCES RELATING TO THE REACTION OF THE ENZYME WITH A SUBSTRATE - A method of determining the course of enzyme activity that is variable in time, wherein the activity is probed by conversion of a substrate of the enzyme, includes, in a selected test set up and for a determined substrate of the enzyme, determining the velocity of signal production (dF | 02-24-2011 |
20110053193 | Protein Assay - A method is described for the measurement of thrombin activity in the presence of fibrinogen, or for the measurement of the functionality of fibrinogen in the presence of thrombin. | 03-03-2011 |
20110091918 | HETEROGENEOUS COAGULATION TEST - Within the field of coagulation diagnostics, in heterogeneous methods for determining the activity of blood coagulation factors and also in heterogeneous methods for determining anticoagulants which inhibit the activity of blood coagulation factors, a sample is contacted with a cleavable substrate, and the amount of uncleaved substrate is subsequently determined. | 04-21-2011 |
20110097754 | METHOD FOR MEASURING ACTIVATED FACTOR VII LEVEL IN A SAMPLE - The present disclosure relates to a method for measuring the activated factor VII level in a sample to be tested, including the steps of: a) mixing the test sample with a plasma free of factor VII (FVII) and free of at least another factor selected from among factor VIII (FVIII), factor IX (FIX), and factor XI (FXI), the test sample+plasma having a final FVII+FVIIa concentration of 10 pM to 80 pM; b) adding initiating components from the thrombin generation reaction; c) obtaining a thrombogram when carrying out a thrombin generation test (TGT) on the mixture from step b); d) comparing at least one of the thrombogram parameters from step c) with a homologous parameter obtained from standard thrombograms established on the basis of standard samples, the activated factor VII level of which is known and varies with each standard sample; e) deducing, from step d), an activated factor VII level measurement in the test sample. | 04-28-2011 |
20110117586 | Protocol for Risk Stratification of Ischemic Events and Optimized Individualized Treatment - A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood hemostasis parameters. The measured blood hemostasis parameters permit preparation of an individualized assessment of ischemic event risk and individualized treatment of a subject. | 05-19-2011 |
20110129862 | METHOD FOR DETERMINING CAUSE OF THE PROLONGATION OF BLOOD COAGULATION TIME - Provided is a method of accurately and easily determining a cause of the prolongation of blood coagulation time. | 06-02-2011 |
20110143383 | MICROFLUIDIC DEVICE - A microfluidic device comprising a flow channel with an inlet and a gas escape opening is described. The flow channel comprises a liquid flow channel section and a flow controlling section downstream to the liquid flow channel section and upstream to or coinciding with the gas escape opening. The flow controlling section provides a flow resistance to gas, which is sufficiently high to reduce velocity of a capillary flow of a liquid in the liquid flow channel section. | 06-16-2011 |
20110151491 | Portable Coagulation Monitoring Device and Method of Assessing Coagulation Response - A device, system and method is disclosed in which small volume blood samples are subjected to shear forces and shear stresses between two parallel planar surfaces to which linear motion trajectories are imparted. The formation of clots or coagulation of the sample is measured from dynamic mechanical coupling which occurs between the two parallel planar surfaces. Detection of the coagulation response can be achieved through optical probing or by measurement of physical effects of the blood sample binding to the planar surfaces, and restricting movement thereof. | 06-23-2011 |
20110177541 | METHOD FOR ADJUSTING THE COAGULATION TIME IN CALIBRATOR OR CONTROL PLASMAS - A method for adjusting the coagulation time during the manufacture of calibrators and controls produced from frozen plasma or plasma treated for lyophilization thereof, for haemostatis tests relating to assaying and to monitoring anticoagulant treatments in a patient. The plasmas selected to prepare the calibrator plasmas or the control plasmas are treated with a view to lyophilization and supplemented with different predefined doses of a drug and a procoagulant factor. | 07-21-2011 |
20110223627 | MICROFLUIDIC FLOW ASSAY FOR MEASURING HEMOSTATIC PHENOTYPES - A microfluidic-based flow assay and methods of manufacturing the same are provided. Specifically, the microfluidic flow assay includes a micropatterned surface that induces clot formation and an array of microfluidic channels though which blood flows. The micropatterned surface contains two clotting stimuli, one for inducing platelet adhesion and another for inducing the coagulation cascade. | 09-15-2011 |
20110269160 | METHOD AND MEDIUM FOR DETECTING THE PRESENCE OR ABSENCE OF STAPHYLOCOCCUS AUREUS IN A TEST SAMPLE - A presence/absence test for | 11-03-2011 |
20110312002 | NMR DETECTION OF COAGULATION TIME - The invention relates to detecting coagulation and coagulation-related activities including agglutination and fibrinolysis of samples. More particularly the invention relates to methods and apparatus for monitoring coagulation and/or obtaining a coagulation time of a sample using NMR-based detectors. | 12-22-2011 |
20120040384 | LYOPHILISED DABIGATRAN - The invention relates to a lyophilised form of dabigatran of formula (I) its use as a calibrator in the assays for the determination of pharmacodinamic effects of dabigatran etexilate as well as such assays per se. In the preparation of the lyophilised standards, dabigatran is dissolved in an aqueous acidic solution before freeze-drying. | 02-16-2012 |
20120040385 | COAGULOGEN RAW MATERIAL, PROCESS FOR PRODUCING THE SAME, AND METHOD AND APPARATUS FOR MEASURING PHYSIOLOGICALLY ACTIVE SUBSTANCE OF BIOLOGICAL ORIGIN USING THE SAME - Disclosed is a technique for obtaining a coagulogen raw material which can irreversibly inactivate the activity of a coagulase while retaining the function of coagulogen in an LAL reagent, a LAL reagent contaminated by an organism-derived biologically active substance or the like, and which can be used in a reagent. An LAL reagent is heated at a predetermined temperature for a predetermined period of time to deactivate only the activity of an enzyme contained in the LAL reagent irreversibly, wherein such an activity inherent in coagulogen that coagulogen can be hydrolyzed with the activated coagulase and converted to coagulin to induce gelatinization or an agglutination reaction is retained. | 02-16-2012 |
20120058500 | PLATELET AGGREGATION USING A MICROFLUIDICS DEVICE - A microfluidics device to provide real time monitoring of platelet aggregation of a biological sample obtained from a subject. The device comprises a channel configured for passage of the biological sample, the channel comprising a protrusion configured to induce an upstream region of shear acceleration coupled to a downstream region of shear deceleration and defining there-between a region of peak rate of shear, the downstream region of shear deceleration defining a zone of platelet aggregation. The device further comprises a platelet detection means for detecting aggregation of platelets in the zone of aggregation as a result of passage of the biological sample through the channel. Methods to assess real time platelet aggregation of a biological sample obtained from a subject are further described. | 03-08-2012 |
20120064551 | METHOD FOR THE PREOPERATIVE DETERMINATION OF THE INTRAOPERATIVE RISK OF BLEEDING OF A PATIENT - In order to determine the intraoperative risk of bleeding preoperatively, both the content of fibrin monomer (FM) and the partial thromboplastin time (PTT) are determined in a blood or plasma sample. | 03-15-2012 |
20120064552 | USING BLOOD CLOT IN MICROFLUIDIC VALVING APPLICATIONS - The present invention provides a method of forming a blood-clot microvalve by heating blood in a capillary tube of a microfluidic device. Also described are methods of modulating liquid flow in a capillary tube by forming and removing a blood-clot microvalve. | 03-15-2012 |
20120064553 | BLOOD COAGULATION TIME PROLONGING AGENT - Provided is a reagent, which prolongs a blood coagulation time sufficiently and enhances an optical change, thereby enabling a correct and high-sensitive blood coagulability test. The present invention provides a blood coagulation time prolonging agent, including, as an active ingredient, a guanidine compound represented by the following formula (1) or an acid addition salt thereof (in the formula, R | 03-15-2012 |
20120107851 | LATERAL FLOW ASSAY DEVICE FOR COAGULATION MONITORING AND METHOD THEREOF - The present invention is directed to a lateral flow assay device for the monitoring and measuring of coagulation and method thereof. Ideally, the invention is directed to a lateral capillary flow device for the monitoring and/or measurement of coagulation in a liquid sample wherein the device comprises a non-porous substrate with a zone for receiving a sample and a defined flow path zone wherein a clotting agent is deposited on at least part of the defined flow path zone to accelerate the coagulation of the liquid sample, enable the formation of an evenly distributed clot along the defined flow path zone and to result in the change in flow rate or cessation of flow of the liquid sample along the defined flow path zone. | 05-03-2012 |
20120135436 | Method of Determining Enzymatic Activity in Biological Media - A reliable, fast and convenient method is provided to determine the change in concentration of enzyme in time in a biological medium in the presence of a signal substrate that corrects for substrate consumption, color-dependency of the signal and non-linearity between the concentration of the leaving group of the signal substrate and the amount of signal. The method comprises the measurement of a calibrator curve in a suitable medium, such as a buffer, to determine the characteristics of the measured curve. These characteristics will then allow to obtain this whole curve or a sufficient part thereof again through a mathematical procedure based on a single-point measurement in a sample of a medium in which the enzyme generation takes place. This has the great advantage that there is no need to measure the whole calibrator curve in each individual medium, since a single-point measurement is adequate. | 05-31-2012 |
20120142036 | Enhanced Cleavage of Von Willebrand Factor by ADAMTS13 - Novel methods are described for measuring the rate of ADAMTS13-mediated cleavage of von Willebrand Factor (VWF) multimers. Through the use of the reagent, ristocetin, the method can advantageously be performed in the absence of an applied shear stress or added denaturing agent. Also described are methods for diagnosing ADAMTS13-associated disorders and methods for providing improved treatment of those disorders by evaluating the efficacy of the treatment using the methods as described. | 06-07-2012 |
20120178114 | METHODS AND DEVICES FOR DETECTING THROMBIN GENERATION - Methods and devices for detecting thrombin generation are disclosed. Generally, the methods include combining a blood sample with a reagent composition so that reaction of the reagent composition and thrombin, if present in the sample, produces a detectable signal; and detecting the detectable signal. Generally, the devices include a fluid-tight material forming at least one passageway; a first chamber in fluid communication with at least one passageway; and at least one reagent disposed on a surface of or contained in either a chamber or a passageway. In some embodiments, the passageway is configured to permit capillary flow of fluid, while in other embodiments, fluid flow is accomplished through a pump functionally linked to at least one passageway. In some embodiments, the device may further include a signal detector positioned to detect a signal generated in a chamber or passageway. In certain embodiments, the device may further include a microprocessor functionally linked to the signal detector. | 07-12-2012 |
20120190052 | Method of determining factor XIII by means of NAD(P)H-analogues - The invention is in the field of in-vitro diagnostics and relates to a photometric method for determining the blood-clotting factor XIII (factor XIII, F XIII) with the aid of NAD(P)H analogues, and a test kit for carrying out the method. The invention is in the field of in-vitro diagnostics and relates to a photometric method for determining the blood-clotting factor XIII (factor XIII, F XIII) with the aid of NAD(P)H analogues, and a test kit for carrying out the method. | 07-26-2012 |
20120202232 | Heparin-insensitive Method for Determining Direct Coagulation Factor Inhibitors - The invention is in the field of coagulation diagnostics and relates to a heparin-insensitive method for determining direct coagulation factor inhibitors in a sample, in particular direct thrombin and factor Xa inhibitors. | 08-09-2012 |
20120231485 | METHOD FOR MONITORING ANTICOAGULANT THERAPY - A method of measuring the combined activity of both and only coagulation factors II and X for the purpose of monitoring anticoagulant therapy, and kits for using the method. The method involves mixing of test plasma from a human to be tested with specially prepared plasma deficient in both and only coagulation factors II and X but with normal levels of other factors (referred to herein as Fiix-deficient plasma or Fiix plasma), in order to correct for any possible deficiency in other coagulation factors than FII and FX in the test sample. By adding a coagulation reagent and calcium, the generation of thrombin or fibrin can be measured. Kits of the invention comprise a coagulation reagent, calcium and specially made plasma that is deficient in both and only factor II and factor FX. | 09-13-2012 |
20120237960 | Devices and Methods for Determining the Platelet Function in a Centrifugal Analyzer - The invention lies in the field of platelet function diagnostics and relates to devices and methods for determining the platelet function in a centrifugal analyzer. | 09-20-2012 |
20120244564 | ULTRASOUND-BASED METHOD AND RELATED SYSTEM TO EVALUATE HEMOSTATIC FUNCTION OF WHOLE BLOOD - Method and systems for of evaluating a mechanical property of a material by applying force to the material sufficient to physically displace a portion of the material, measuring displacement of the material, adaptively adjusting the force when the displacement measured is not within a predetermined range of displacement values, wherein the force is increased or decreased depending upon whether the measured displacement is below or above the predetermined range, respectively, and computing a mechanical property value resultant from the displacement of the material | 09-27-2012 |
20120252043 | BLOOD COAGULATION TIME DETERMINATION METHOD AND APPARATUS - The invention relates to a method for determining the coagulation time of a sample fluid containing blood components by means of a resonator whose vibration parameters are measured and then used as a basis for determining the sample fluid viscosity change, which resonator has an at least partially adhesive surface contacting said sample fluid. The invention is characterized by preincubation of said surface with a preincubation fluid containing blood components, which preincubation fluid has a known way of interacting with the coagulation system, thus resulting in anchoring sites to be formed on the adhesive areas of said surface. | 10-04-2012 |
20120252044 | Controls and kit for thrombocyte activity tests - The present invention is in the field of coagulation diagnostics and relates to a kit and method for preparing controls for use in test methods for determining thrombocyte function. | 10-04-2012 |
20120264150 | DETECTION OF RESTENOSIS RISK IN PATIENTS RECEIVING A STENT BY MEASURING THE CHARACTERISTICS OF BLOOD CLOTTING INCLUDING THE MEASUREMENT OF MAXIMUM THROMBIN-INDUCED CLOT STRENGTH - Provided is a method of selecting a stent for implantation in the circulatory system of a human being. The method comprises obtaining a blood sample from a patient who requires implantation of a stent and testing said blood sample to determine a platelet coagulability level. The determined platelet coagulability level of said blood sample is compared with a threshold level of blood platelet coagulability. A determined platelet coagulability level above said threshold level indicates that a risk of restenosis is relatively high. If the determined platelet coagulability level is below said threshold level, a bare metal stent is selected. If the determined platelet coagulability level is at or above said threshold level, a drug-eluting stent is selected. | 10-18-2012 |
20120295291 | Method for Determining the Risk of Clopidogrel Resistance - The present invention relates to a method for identifying patients for whom there is a high probability of their not benefiting from therapy with clopidogrel. It was found that the thrombocyte activity of a patient makes it possible to establish, even before the intake of clopidogrel, whether the patient has an increased risk of clopidogrel resistance (high on-treatment platelet reactivity). | 11-22-2012 |
20120309035 | STABLE SOLUTION - The present invention relates to a stable solution comprising a stable solution without coagulation factor XII and with a defined amount of ionized calcium. The stable solution may be used as control material for coagulation analysis. Further, a method for producing said stable solution, as well as methods for assessing coagulation system status in a subject and kits, is encompassed herein. | 12-06-2012 |
20120329082 | Devices, Systems and Methods For Evaluation of Hemostasis - Provided are devices, systems and methods for evaluation of hemostasis. Also provided are sound focusing assemblies. | 12-27-2012 |
20130023001 | USE OF A SUBSTRATE IN A METHOD FOR MEASURING THE ACTIVITY OF PROTEOLYTIC ENZYMES - The disclosure relates to the use of a proteolytic enzyme substrate of general formula: Q | 01-24-2013 |
20130023002 | USE OF A SUBSTRATE IN A METHOD FOR MEASURING THE ACTIVITY OF AVAILABLE PROTEOLYTIC ENZYMES - The disclosure relates to the use of a proteolytic enzyme substrate of general formula: Q | 01-24-2013 |
20130052672 | KIT FOR MEASURING THE THROMBIN GENERATION IN A SAMPLE OF A SAMPLE OF A PATIENT'S BLOOD OR PLASMA - The invention provides a kit for measuring the thrombin generation in a sample of a patient's blood or plasma, or in a sample of clotting factors. The kit contains lyophilized tissue factor/phospholipid-complex and a lyophilized mixture containing a thrombin-substrate and CaCl | 02-28-2013 |
20130065260 | Compositions, Methods and Uses for Simultaneous Assay of Thrombin and Plasmin Generation - Embodiments of the present invention report compositions and methods of analyzing thrombin and plasmin generation in a sample from a subject. In certain embodiments, the methods may comprise introducing at least one activator of coagulation and at least one activator of fibrinolysis to a sample and analyzing the sample for kinetic parameters related to thrombin and plasmin generation. In other embodiments, assays disclosed herein concern assessing net hemostatic balance of a subject for diagnostic and/or therapeutic applications. | 03-14-2013 |
20130089881 | TESTING A MAMMAL FOR PRESENCE, PROGRESSION OR STAGE OF A SHOCK CONDITION - Methods and kits for diagnosis and staging of non-septic shock are presented in which one or more protease activities are measured from a biological sample to so identify and/or stage non-septic shock. Most preferably, at least two protease activities are correlated, however, additional or alternative markers may also be measured. | 04-11-2013 |
20130102015 | COMPOSITION FOR THE DETERMINATION OF COAGULATION CHARACTERISTICS OF A TEST LIQUID - The present invention is directed to a diagnostic composition for use in the viscoelastic analysis of a test liquid, and to a container ( | 04-25-2013 |
20130157298 | 2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors - The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed. | 06-20-2013 |
20130177933 | Characterization of Subvisible Particles Using a Particle Analyzer - The present specification discloses methods of characterizing a population of particles using a particle analyzer. Particles may be characterized by size, absolute number, whether the particle is non-proteinaceous or proteinaceous, whether a proteinaceous particle has or lacks a certain physical property, or any combination thereof. | 07-11-2013 |
20130189718 | ASSAYS FOR DETECTION OF GLYCOSAMINOGLYCANS - Disclosed herein are novel methods, assays and kits useful for the diagnosis and monitoring of subjects with mucopolysaccharidoses (MPS), The methods, assays and kits are particularly useful for detecting the presence of one or more glycosaminoglycans which correlate to MPS and its severity in a variety of biological samples. | 07-25-2013 |
20130224777 | Screening method for finding samples having antiphospholipid antibodies - The present invention is in the field of coagulation diagnostics and relates to a screening process for finding samples containing antiphospholipid antibodies (lupus anticoagulants), wherein the platelet aggregation-stimulating action of said antiphospholipid antibodies is determined in vitro. | 08-29-2013 |
20130273584 | SERUM PREPARATION - This invention relates to the use of clotting compositions containing prothrombin activators to produce high quality blood serum samples for pathology and other biological assays, and to containers containing such clotting compositions, and related methods of use. | 10-17-2013 |
20130302839 | ANALYSIS OF DIRECT FACTOR Xa INHIBITORS - The present invention relates to a method for detecting at least one direct factor Xa inhibitor in a sample other than citrate plasma, comprising the step of mixing a sample containing a factor Xa inhibitor with a composition containing factor Xa under conditions which allow the factor Xa to release a detectable substance from a chromogenic substrate. | 11-14-2013 |
20130309701 | NUCLEIC ACID FRAGMENT ENCODING A HORSESHOE CRAB-DERIVED PRO-CLOTTING ENZYME - Objects of the present invention are to provide a DNA fragment encoding a | 11-21-2013 |
20130323765 | Method For Determining The Activity Of A Proteolytic Coagulation Factor In A Sample - A method for determining the activity of a proteolytic coagulation factor in a sample may include (a) providing and incubating a reaction mixture comprising (i) the sample, (ii) an agent for direct or indirect activation of the proteolytic coagulation factor in the sample, (iii) a cleavable substrate which has at least one cleavage site for the activated coagulation factor, (iv) a solid phase to which the cleavable substrate is bound or becomes bound during the incubation; (b) separating off the solid phase; and (c) determining the amount of solid-phase-bound, uncleaved substrate, wherein the determined amount of solid-phase-bound, uncleaved substrate indicates a quantitative measure of the activity of the proteolytic coagulation factor in the sample. | 12-05-2013 |
20130344519 | METHODS AND SYSTEMS FOR ASSESSMENT OF TURBIDITY KINETICS (WAVEFORM ANALYSIS) IN COAGULATION TESTING - In some embodiments, a method is provided that includes (1) obtaining a plasma sample from a patient; (2) performing a coagulation assay on the plasma sample; (3) measuring a coagulation property of the plasma sample using a coagulation analyzer so as to generate measured data; (3) performing waveform analysis on the measured data so as to obtain turbidity characteristics; and (4) employing the waveform analysis to determine a coagulation status of the coagulation assay not provided by the coagulation analyzer. Numerous other embodiments are provided. | 12-26-2013 |
20130344520 | Thrombin Substrate and Assay for Determining the Level of Bioactive Thrombin in a Sample - Substrates for thrombin and assays for determining the level of bioactive thrombin in a sample are disclosed, wherein the substrate has the general formula: A-X—Z-A′ wherein one of either A or A′ comprises a luminescent chelate and the other one of A or A′ comprises a first partner of a binding pair, X forms a tri- or tetra-peptide, and Z comprises a linker. | 12-26-2013 |
20140024059 | APPARATUS AND METHODS FOR ANALYZING FLUID VARIABLES - Methods and devices for analyzing fluid variables. The devices analyze fluid variables by measuring cessation of fluid flow through the medium or a change in flow rate due to an inherent property of the fluid variable, or due to a modification of the fluid variable as the fluid migrates through the medium; or by measuring relative rates of capillary flow down two or more arms of a common element of porous media in some alternatives, converging in which at least one of the arms has been modified by the addition of flow-modifying agents which affect the flow rate in response to the concentration of the analyte; or by detecting changes in the rate of the capillary flow of the sample fluid along a path through an element of porous media, or through multiple elements of porous media. | 01-23-2014 |
20140038214 | MICROFLUIDIC FLOW ASSAY AND METHODS OF USE - A microfluidic-based flow assay and methods of manufacturing the same are provided. Specifically, the microfluidic flow assay includes a substrate surface comprising lipid coated particles and microfluidic channels through which a blood product can flow. The lipid coated particles comprise functional molecules that can induce or inhibit the coagulation cascade. | 02-06-2014 |
20140051103 | PROCEDURE FOR BIPHASIC PREPARATION OF LIPOSOMES AND APPLICATION THEREOF IN MANUFACTURING DIAGNOSTIC REAGENTS - The invention relates to a procedure for biphasic preparation of liposomes, in the course of which technically simple and cheap mechanical mixing methods are used to commingle non-polar organic phase containing an individual mixture of natural and synthetic phospholipids and polar aqueous (buffer) phase not miscible with it, resulting in a liposome emulsion of a unique structure. Furthermore, the invention comprises embodiments of the procedure related to the in vitro diagnostic use of liposomes prepared in this way, when protein type active components are anchored to the surface of liposome membranes without application of any detergents and non-protein type active components are simply mixed with the liposome emulsion of a unique structure. In one of the possible embodiments of the procedure a Prothrombin Time (PT) reagent is prepared. Another possible embodiment of the procedure is the preparation of an activated partial thromboplastin time (APTT) reagent. | 02-20-2014 |
20140057308 | METHOD FOR DETECTING PROTEIN S ABNORMALITES - A method of detecting protein S abnormalities of the invention includes the steps of: measuring an activity value of total protein S and a protein content of total protein S in a specimen, and comparing between the protein activity of the total protein S and the protein content of total protein S, which are obtained from the measurements. | 02-27-2014 |
20140080160 | Assessment of Protein C Anticoagulant Pathway By Thrombin Generation Assay In The Presence of Endothelial Cells - The present application discloses the effects of endothelial cell-dependent activation of the protein C anticoagulant pathway via detection of thrombin generation correlated with the activation of the protein C anticoagulant pathway in plasma in the presence of endothelial cells using a fluorogenic substrate-based thrombin generation assay. | 03-20-2014 |
20140087403 | LOW-VOLUME COAGULATION ASSAY - Compositions and methods for measuring coagulation parameters using very small volumes of blood are provided. Advantageously, the methods described herein can be performed from a single drop of blood (about 20 μL) while generally leaving enough sample to perform other measurements, optionally in a multiplexed format. The methods and devices do not require a skilled operator and can be performed at the point of service, which can be an important feature for managing blood coagulation disorders and treatments thereof. | 03-27-2014 |
20140106382 | CAPILLARY FLUID FLOW MEASUREMENT AND CAPILLARY FLOW DEVICE THEREFORE - The present invention relates to a liquid flow device, in particular a capillary testing device provided as a chip, comprising a second pathway which intersects the first pathway at a downstream point of convergence, so that the two pathways share an outlet and when liquid in the second pathway reaches the point of convergence, liquid flow in the first pathway stops. Means for measuring the distance travelled by liquid in the first pathway are provided to determine the extent of liquid flow and to enable correlation with the amount of analyte in the liquid. | 04-17-2014 |
20140106383 | Electrochemical Determination of Factor XA Inhibitors - Methods and devices for determining factor Xa inhibitors, in particular heparins and fractionated or low-molecular-weight heparins, as well as direct factor Xa inhibitors in blood samples. The methods include contacting a blood sample with a detection reagent that contains at least one thrombin substrate having a peptide residue that can be cleaved by thrombin and is amidically bound via the carboxyl end to an electrogenic substance, and with a known amount of factor X reagent and an activator reagent which induces the conversion of factor X into factor Xa. Subsequently, in a second step, the amount or activity of the electrogenic substance that is cleaved from the thrombin substrate by the factor Xa-mediated thrombin activation and/or the time course thereof is determined as the measurement signal using electrochemical methods. In a third step, the amount of the factor Xa inhibitor in the sample of the blood to be analyzed or a measured quantity that correlates therewith, in particular a clotting time that correlates therewith, is determined on the basis of this measurement signal. | 04-17-2014 |
20140127725 | METHOD FOR DETECTING LUPUS ANTICOAGULANTS - Provided is the development of a convenient LA detection method in which even a sample derived from a patient who receives anticoagulant therapy of warfarin, heparin or the like, is not affected by the anticoagulant therapy, discrimination from the deficiency of blood coagulation factors is enabled, and healthy person's plasma is not used. The method for detecting lupus anticoagulant includes the following steps (A), (B) and (C): (A) a step of adding a buffer solution composition containing blood coagulation factors to each of a blood sample and a diluted sample of the blood sample before measurement or at the time of measurement of the blood coagulation time; (B) a step of measuring the blood coagulation times for the various samples of step (A); and (C) a step of comparing the blood coagulation times for the various samples obtained in step (B). | 05-08-2014 |
20140127726 | METHOD OF MEASURING BLOOD COAGULATION TIME TO DETECT LUPUS ANTICOAGULANTS - Provided is a method of measuring blood coagulation time, the method being capable of LA detection easily and with high sensitivity as compared with the method recommended by the ISTH, without being affected by deficiency of blood coagulation factors even in a blood sample of a warfarin taker, a person who suffers from vitamin K deficiency, or a hepatic failure patient. Disclosed is a method of measuring the blood coagulation time to detect lupus anticoagulant, the method including adding a buffer solution composition containing blood coagulation factors to a blood sample before measurement or at the time of measurement of the blood coagulation time, and measuring the blood coagulation time. | 05-08-2014 |
20140127727 | BLOOD COAGULATION TIME PROLONGING AGENT - Provided is a reagent, which prolongs a blood coagulation time sufficiently and enhances an optical change, thereby enabling a correct and high-sensitive blood coagulability test. The present invention provides a blood coagulation time prolonging agent, including, as an active ingredient, a guanidine compound represented by the following formula (1) or an acid addition salt thereof (in the formula, R | 05-08-2014 |
20140147871 | METHOD AND MEDIUM FOR DETECTING THE PRESENCE OR ABSENCE OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS IN A FIRST GENERATION BIOLOGICAL TEST SAMPLE - A presence/absence test for | 05-29-2014 |
20140186865 | METHOD FOR ASSAYING PLASMINOGEN IN A LIQUID MEDIUM, ASSOCIATED COMPOSITIONS AND KIT - The invention relates to a method for assaying plasminogen in a sample comprising a step consisting in particular of reacting a streptokinase (R1), and a streptokinase activator, with a control solution or a diluted plasma sample, in which the streptokinase activator is selected from the group comprising a fibrin DD fragment and/or at least one DD fragment derivative. | 07-03-2014 |
20140212901 | NMR METHODS FOR MONITORING BLOOD CLOT FORMATION - The invention features a method of monitoring a clotting process by measuring a signal characteristic of the NMR relaxation of water in a sample undergoing clotting to produce NMR relaxation data and determining from the NMR relaxation data a magnetic resonance parameter of water in the sample characteristic of the clots being formed. | 07-31-2014 |
20140212902 | HEAT-TREATED LIMULUS AMEBOCYTE LYSATES - The application provides heat-treated | 07-31-2014 |
20140234880 | METHODS OF DETECTION OF CANCER USING PEPTIDE PROFILES - The disclosed methods address the identification and monitoring of cancer in a subject using serum peptide profiles. Such profiles allow the detection of the differential presence of certain serum peptide markers in comparison with controls. The profiles can be determined employing mass spectrometry. | 08-21-2014 |
20140242621 | METHOD FOR DETERMINING PROTEIN S ACTIVITY - The invention relates to a method for determining the protein Ca-cofactor activity of protein S, wherein the protein Ca-cofactor activity of protein S is measured in a first reaction volume in the absence of a protein S inhibitor and in a second reaction volume in the presence of a protein S inhibitor. The protein Ca-cofactor activity of protein S is determined by calculating the quotient of the assay result of the first reaction volume and the assay result of the second reaction volume. | 08-28-2014 |
20140255961 | SYNTHETIC MICROFLUIDIC SYSTEMS FOR WOUND HEALING AND HEMOSTASIS - A method of assaying wound healing can include: growing cells on the matrix in the first flow channel; introducing an agent that removes the matrix from the junction; introducing a matrix material into the second flow channel so as to form the second matrix in the second flow channel and junction; and detecting cellular migration into the junction onto the second matrix. The agent that removes the matrix can include a biomolecule or chemical agent. The method can include removing cells in the matrix in the junction before introducing the matrix material into the second flow channel. A bioactive agent can be introduced into the junction to determine if it modulates cellular migration and/or clot formation into the intersection openings of tissue and vascular channels. | 09-11-2014 |
20140273040 | METHOD FOR PRODUCING RECOMBINANT PROTHROMBIN, VECTOR DNA, AND REAGENT KIT - The present invention provides a method for producing recombinant prothrombin. The method comprises: providing a vector DNA into which a gene encoding a tag and a gene encoding prothrombin are incorporated, wherein the tag is selected from the group consisting of MBP, SUMO, and NusA; and expressing a tag fusion type prothrombin in a lepidopteran insect or cultured cells of the lepidopteran insect. | 09-18-2014 |
20140295470 | METHOD AND REAGENT KIT FOR MEASURING ACTIVATED PARTIAL THROMBOPLASTIN TIME - The present invention provides a method for measuring activated partial thromboplastin time. The method comprises: a first mixing step of mixing a blood plasma with a first reagent, wherein the first reagent comprises an activator and phosphatidylglycerol at a concentration equal to or greater than 25 μg/mL; a second mixing step of mixing a sample obtained in the first mixing step with a second reagent comprising a calcium salt; and a step of measuring coagulation time of the sample obtained in the second mixing step. | 10-02-2014 |
20140295471 | DETERMINATION OF THE THROMBOGENIC POWER OF HUMAN IMMUNOGLOBULINS - A kit for the determination of the thrombogenic power of human immunoglobulins contained in a biologically acceptable product. Also a process making it possible to determine the thrombogenic power linked to the presence of activated Factor XI and/or activated Factor IX and/or activated Factor XII, and/or activated Factor VII and/or activated Factor X in a sample capable of being administered to humans. | 10-02-2014 |
20140295472 | Paper Based Diagnostic Test - A device utilizing agglutination and its method of use to diagnose diseases or conditions. The diagnostic device may comprise a substrate having pores, an agglutination zone, and a test readout zone wherein said agglutination zone is functionalized with an agglutinating agent to cause agglutination of the sample. | 10-02-2014 |
20140315228 | APPARATUS AND METHOD FOR ANALYZING BLOOD CLOTTING - Systems, apparatuses and methods include evaluation the clotting time or strength of clotting in the presence of various clot-affecting reagents to obtain a profile of clot analysis for determination of bleeding complications. The various reagents may be included in a single cartridge for use in a blood clotting analysis device. | 10-23-2014 |
20140322736 | METHOD FOR THE PRODUCTION OF HUMAN THROMBIN AND USES THEREOF - The present invention disclosed the cloning and the purification of a mutant of prethrombin-2, which contains a thrombin cleavage site instead of a factor Xa cleavage site. The stable mutant prethrombin-2 is able to convert itself autocatalytically into active α-thrombin in the absence of ecarin or factor Xa. The new concept of signal amplification using self-replicating enzymes can be applied to improve sensitivity of α-thrombin assays and also for the preparation of different enzymes. | 10-30-2014 |
20140349325 | METHOD AND MEDIUM FOR DETECTING THE PRESENCE OR ABSENCE OF AN ANTIBIOTIC RESISTANT PATHOGENIC STAPHYLOCOCCI IN A TEST SAMPLE - A method and medium for detecting the presence or absence of a targeted strain of antibiotic resistant pathogenic | 11-27-2014 |
20150050676 | Method for Measurement of Peptidic Degradation Products of a Proteolytic Cascade in Blood Samples - The invention discloses a method for measurement of peptidic degradation products of a proteolytic cascade (for example, the renin-angiotensin system (RAS) and the bradykinin system) in biological samples, especially blood samples, wherein the sample is incubated until a steady state equilibrium is reached for at least one peptidic degradation product involved in said proteolytic cascade and wherein said at least one peptidic degradation product in steady state equilibrium of the proteolytic cascade is quantified in the sample. | 02-19-2015 |
20150050677 | METHODS AND SYSTEMS FOR MEASURING WHOLE BLOOD PLATELET REACTIVITY - The invention relates to a novel approach and related methods and systems, which provide accurate and easily implemented measurement and analyses of whole blood platelet reactivity, and impact on treatment thereof. | 02-19-2015 |
20150093770 | METHOD AND DEVICE FOR THE DETERMINATION OF PLATELET FUNCTION UNDER FLOW CONDITIONS - The invention lies in the area of platelet function diagnostics and relates to a method for the determination of platelet function under flow conditions as well as a device for the implementation of this method. The method is particularly suitable for the determination of the effect of clopidogrel and of other P2Y(12) antagonists with antithrombotic activity as well as the determination of P2Y(1) antagonists with antithrombotic activity. | 04-02-2015 |
20150111235 | METHOD FOR DETERMINING CAUSE OF THE PROLONGATION OF BLOOD COAGULATION TIME - Provided is a method of accurately and easily determining a cause of the prolongation of blood coagulation time. | 04-23-2015 |
20150299759 | METHOD FOR THROMBOGENICITY TESTING OF IMPLANTED MEDICAL DEVICE - A method of determining the thrombogenicity of an implantable medical device is disclosed. The implanted device is exposed in vitro to platelet rich plasma, the activity of an indicator is assayed, and the thrombogenicity is determined. | 10-22-2015 |
20150301018 | LOW-VOLUME COAGULATION ASSAY - Compositions and methods for measuring coagulation parameters using very small volumes of blood are provided. Advantageously, the methods described herein can be performed from a single drop of blood (about 20 μL) while generally leaving enough sample to perform other measurements, optionally in a multiplexed format. The methods and devices do not require a skilled operator and can be performed at the point of service, which can be an important feature for managing blood coagulation disorders and treatments thereof. | 10-22-2015 |
20150308970 | METHODS FOR MONITORING TIGHT CLOT FORMATION - The invention features a method of monitoring a clotting process by measuring a signal characteristic of the NMR relaxation of water in a sample undergoing clotting to produce NMR relaxation data and determining from the NMR relaxation data a magnetic resonance parameter of water in the sample characteristic of the clots being formed. | 10-29-2015 |
20150316460 | METHOD FOR MEASURING COAGULATION OF BLOOD SAMPLES USING VISCOELASTIC TESTS (VET) - This disclosure provides a method for measuring coagulation of blood or plasma samples using viscoelastic tests (VET) wherein the measuring is performed in the presence of immobilised endothelial cells. | 11-05-2015 |
20150316565 | Methodologies and Reagents for Detecting Fibrinolysis and Hyperfibrinolysis - In some embodiments, the invention provides methods for detecting fibrinolysis or hyperfibrinolysis in a blood sample from a patient. The method includes subjecting a first portion of a blood sample comprising reduced platelet function to viscoelastic analysis in the absence of an inhibitor of fibrinolysis to obtain the coagulation characteristic of the first portion at the time point; and subjecting a second portion of the blood sample comprising reduced platelet function to viscoelastic analysis in the presence of an inhibitor of fibrinolysis to obtain a coagulation characteristic of the second portion at a time point; wherein a difference between the coagulation characteristic of the first portion and the coagulation characteristic of the second portion indicates fibrinolysis or hyperfibrinolysis in the blood sample. | 11-05-2015 |
20150322480 | METHOD FOR MEASURING THROMBIN GENERATION - It is an object of the present invention to provide a measurement method capable of easily evaluating combined effects in a single assay system, when antithrombotic agents having different mechanisms of action are used in combination. A method for measuring thrombin generation comprising: (1) a step of adding an anticoagulant, a P2Y | 11-12-2015 |
20150344935 | ANALYSIS OF DIRECT FACTOR Xa INHIBITORS - The present invention relates to a method for detecting at least one direct factor Xa inhibitor in a sample other than citrate plasma, comprising the step of mixing a sample containing a factor Xa inhibitor with a composition containing factor Xa under conditions which allow the factor Xa to release a detectable substance from a chromogenic substrate. | 12-03-2015 |
20150369829 | NMR DETECTION OF COAGULATION TIME - The invention relates to detecting coagulation and coagulation-related activities including agglutination and fibrinolysis of samples. More particularly the invention relates to methods and apparatus for monitoring coagulation and/or obtaining a coagulation time of a sample using NMR-based detectors. | 12-24-2015 |
20160018421 | NMR METHODS FOR MONITORING BLOOD CLOT FORMATION - The invention features a method of monitoring a clotting process by measuring a signal characteristic of the NMR relaxation of water in a sample undergoing clotting to produce NMR relaxation data and determining from the NMR relaxation data a magnetic resonance parameter of water in the sample characteristic of the clots being formed. | 01-21-2016 |
20160032355 | Detection and Classification of an Anticoagulant Using A Clotting Assay - In some embodiments, the invention provides methods for detecting and/or classifying an anticoagulant at a therapeutically relevant amount or higher in a patient, including subjecting a sample of a control blood component (known not to contain the anticoagulant) to a clotting assay in the presence of a Factor Xa reagent to obtain a control clotting measurement; and subjecting a sample of a blood component from a patient suspected of having the anticoagulant to the clotting assay in the presence of the Factor Xa reagent to obtain a patient clotting measurement, wherein the patient clotting measurement sample greater than the control clotting measurement indicates the presence of the anticoagulant at a therapeutically relevant amount or higher in the patient. In some embodiments, the invention includes methods for classifying an anticoagulant as an anti-Factor Xa or a direct thrombin inhibitor anticoagulant using a clotting assay in the presence of an ecarin reagent. | 02-04-2016 |
20160047828 | METHOD AND A DEVICE FOR CHARACTERIZING THE COAGULATION OR SEDIMENTATION DYNAMICS OF A FLUID SUCH AS BLOOD OR BLOOD PLASMA - A method of characterizing the coagulation or sedimentation dynamics of a fluid such as whole blood, a blood fraction, or blood plasma, the method including: illuminating a sample of the fluid with a beam of coherent light; acquiring a time series of images of a speckle pattern generated by interaction between the sample and the spatially coherent light beam; and processing the time series of images; wherein the processing step includes calculating a function representative of the variation in the speckle pattern between two or more images of the series. The invention also provides a device for implementing such a method. | 02-18-2016 |
20160053299 | Protein Assay - A method is described for the measurement of thrombin activity in the presence of fibrinogen, or for the measurement of the functionality of fibrinogen in the presence of thrombin. | 02-25-2016 |
20160069913 | MICROFLUIDIC CHIP-BASED, UNIVERSAL COAGULATION ASSAY - A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting/coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and/or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay. | 03-10-2016 |
20160069914 | THE DETECTION OF RESTENOSIS RISK IN PATIENTS RECEIVING A STENT - Provided is a method of selecting a stent for implantation in the circulatory system of a human being. The method comprises obtaining a blood sample from a patient who requires implantation of a stent and testing said blood sample to determine a platelet coagulability level. The determined platelet coagulability level of said blood sample is compared with a threshold level of blood platelet coagulability. A determined platelet coagulability level above said threshold level indicates that a risk of restenosis is relatively high. If the determined platelet coagulability level is below said threshold level, a bare metal stent is selected. If the determined platelet coagulability level is at or above said threshold level, a drug-eluting stent is selected. | 03-10-2016 |
20160076077 | METHOD FOR THROMBOGENICITY TESTING OF IMPLANTED MEDICAL DEVICE - A method of determining the thrombogenicity of an implantable medical device is disclosed. The implanted device is exposed in vitro to platelet rich plasma, the activity of an indicator is assayed, and the thrombogenicity is determined. | 03-17-2016 |
20160076078 | REAGENT FOR MEASURING TOTAL PROTEIN S ACTIVITY - A reagent is used for measuring a total protein S activity in a specimen of a patient to detect protein S abnormality. The reagent includes a first reagent containing at least activated protein C, a first phospholipid, a first surfactant, and calcium ions; a second reagent containing at least activated blood coagulation factor V, the first phospholipid, the first surfactant, and the calcium ions; and a third reagent containing at least activated blood coagulation factor X, prothrombin, a substrate of thrombin, a second phospholipid having a composition different from that of the first phospholipid, and the calcium ions. The first reagent, the second reagent, and the third reagent are prepared separately so that the first reagent, the second reagent, and the third reagent are sequentially applied to the specimen. | 03-17-2016 |
20160091507 | SENSORS FOR ASSAYING COAGULATION IN FLUID SAMPLES - The present invention relates to analytical testing devices including micro-environment sensors and methods for assaying coagulation in a fluid sample applied to the micro-environment sensors, and in particular, performing one or more types of coagulation assays using one or more micro-environment sensors in a single point of care combined test cartridge. For example, the present invention may be directed to test sensor including at least one transducer coated with a polymer layer. The polymer layer comprises a thrombin-cleavable peptide with a detectable moiety. | 03-31-2016 |
20160091509 | CARTRIDGE DEVICE WITH SEGMENTED FLUIDICS FOR ASSAYING COAGULATION IN FLUID SAMPLES - The present invention relates to analytical testing devices comprising segmented fluidics and methods for assaying coagulation in a fluid sample received within the segmented fluidics. For example, the present invention may be directed to sample analysis cartridge including an inlet chamber, a first conduit comprising a first junction configured to split a biological sample into at least first and second segments, a second conduit comprising a first reagent, a first sensor region, and a first fluidic lock valve, and a third conduit comprising a first flow restrictor region, a second reagent, and a second sensor region. The sample analysis cartridge further includes a pump configured to independently mix the first segment in the second conduit and the second segment in the third conduit, and independently position the first segment over the first sensor region and position the second segment over the second sensor region. | 03-31-2016 |
20160091510 | CARTRIDGE DEVICE WITH FLUIDIC JUNCTIONS FOR COAGULATION ASSAYS IN FLUID SAMPLES - The present invention relates to analytical testing devices comprising fluidic junctions and methods for assaying coagulation in a fluid sample received within the fluidic junctions. For example, the present invention may be directed to a sample analysis cartridge including an inlet chamber, a first conduit comprising a first junction configured to split a biological sample into at least first and second segments, a second conduit comprising a first reagent, a first sensor region, and a first fluidic lock valve, and a third conduit comprising a second reagent, a second sensor region, and a second fluidic lock valve. The sample analysis cartridge further includes a pump configured to push the first segment over the first sensor region to the first fluidic lock valve, and push the second segment over the second sensor region to the second fluidic lock valve. | 03-31-2016 |
20160091511 | SINGLE CHANNEL CARTRIDGE DEVICE FOR COAGULATION ASSAYS IN FLUID SAMPLES - The present invention relates to analytical testing devices comprising a single channel with micro-environment sensors and methods for assaying coagulation in a fluid sample applied to the micro-environment sensors, and in particular, to performing coagulation assays using a single channel with micro-environment sensors in a point of care test cartridge. For example, the present invention may be directed to a sample analysis cartridge including an inlet chamber configured to receive a biological sample and a conduit fluidically connected to the inlet chamber. The conduit includes a sensor chip including a first micro-environment sensor and a second microenvironment sensor, and a fluid lock valve. The sample analysis cartridge further includes a pump configured to push the biological sample over the first micro-environment sensor and the second microenvironment sensor to the fluidic lock valve such that the biological sample is positioned over the first micro-environment sensor and the second micro-environment sensor. | 03-31-2016 |
20160091513 | TEST STRIPS FOR DETERMINING COAGULATION FACTOR ACTIVITIES - Test strips for determining the activity of a coagulation factor in a blood sample are provided. The strip comprises a support, a sample inlet port for deposition of a blood sample, and a reaction area comprising a blood coagulation reagent. The sample inlet port is connected to the reaction area, and the coagulation reagent comprises blood plasma deficient in the coagulation factor for which activity is to be measured, an ionic citrate source an ionic calcium source, and either one or more coagulation contact phase activator reagents and phospholipids or a mixture of tissue factor and phospholipids. The disclosure further relates to in vitro methods for measuring an activity of a coagulation factor. | 03-31-2016 |
20160091514 | Blood Testing System and Method - Some embodiments of a blood coagulation testing system include an analyzer console device and a single-use cartridge component configured to releasably install into the console device. In some embodiments, the blood coagulation testing system can operate as an automated thromboelastometry system that is particularly useful, for example, at a point-of-care site. | 03-31-2016 |
20160091516 | Blood Testing System and Method - Some embodiments of a blood coagulation testing system include an analyzer console device and a single-use cartridge component configured to releasably install into the console device. In some embodiments, the blood coagulation testing system can operate as an automated thromboelastometry system that is particularly useful, for example, at a point-of-care site. | 03-31-2016 |
20160108457 | METHOD FOR MONITORING ANTICOAGULANT THERAPY - A method of measuring the combined activity of both and only coagulation factors II and X for the purpose of monitoring anticoagulant therapy, and kits for using the method. This is based on the hypothesis that the combined activity of factor II and factor X (FII and FX) more accurately reflects clottability and the antithrombotic effect of VKA anticoagulants in patients than conventional methods (eg PT, P&P). The method involves mixing of test plasma from a human to be tested with specially prepared plasma deficient in both and only coagulation factors II and X but with normal levels of other factors (referred to herein as Fiix-deficient plasma or Fiix plasma), in order to correct for any possible deficiency in other coagulation factors than FII and FX in the test sample. By adding a coagulation reagent and calcium, the generation of thrombin or fibrin can be measured. Kits of the invention comprise a coagulation reagent, calcium and specially made plasma that is deficient in both and only factor II and factor FX. The kit components are suitably lyophilised. | 04-21-2016 |
20160131652 | Method for Determining The Endotoxin Content of An Aluminum Salt Preparation - The present invention provides methods for determining the endotoxin content of an aluminium salt for use in medicine, comprising the steps of:
| 05-12-2016 |
20160161469 | SYNTHETIC MICROFLUIDIC SYSTEMS FOR WOUND HEALING - A method of assaying wound healing can include: growing cells on the matrix in the first flow channel; introducing an agent that removes the matrix from the junction; introducing a matrix material into the second flow channel so as to form the second matrix in the second flow channel and junction; and detecting cellular migration into the junction onto the second matrix. The agent that removes the matrix can include a biomolecule or chemical agent. The method can include removing cells in the matrix in the junction before introducing the matrix material into the second flow channel. A bioactive agent can be introduced into the junction to determine if it modulates cellular migration and/or clot formation into the intersection openings of tissue and vascular channels. | 06-09-2016 |
20160161510 | Blood Testing System Result Interpreter Interface and Methods - Some embodiments described herein provide a system configured to receive blood test result data (from one or more blood analyzer machines) and, based on the blood test result data, to provide a result interpretation output via a user interface to assist the user in identifying a relevant diagnosis or potential health conditions for further investigation. For example, a system may include a blood testing device for generating blood test result data (e.g., measurements related to blood coagulation characteristics or the like) and also include result interpretation interface for providing prompt and meaningful interpretations of the blood test result data. The result interpretation interface may employ blood test result data from a first blood analyzer machine and other blood test result data from other blood analyzer machines that are connected via a direct data cable or a network connection. | 06-09-2016 |
20160161511 | AUTOMATED PLATELET FUNCTION ANALYZER AND ITS ANALYTICAL METHODS - An automated platelet function analyzer includes a sampling vessel, a preparation vessel, an analysis vessel, a sampling needle, a blood sample syringe, an analysis solution syringe, and a blood mixing device. A method for platelet analysis is also disclosed. | 06-09-2016 |
20160178651 | BLOOD SAMPLE DETERMINATION METHOD AND BLOOD SAMPLE ANALYZER | 06-23-2016 |
20160187358 | SENSOR, DETECTION METHOD, DETECTION SYSTEM, AND DETECTION APPARATUS - There is provided a sensor and the like which can detect a first substance with high accuracy. A sensor for detecting whether an analyte contains a first substance, includes a base and a detection section including a second substance immobilized on a surface of the base. The second substance includes an amino acid, a bond which can be cleaved by a reaction with an enzyme, and a first compound which is bonded to the amino acid by the bond and includes a first group capable of bonding to other substances, and the analyte is configured to be introduced to the detection section by being contacted with a third substance which generates the enzyme by a reaction with the first substance. | 06-30-2016 |
20160195560 | SPECIMEN ANALYZING METHOD AND SPECIMEN ANALYZING APPARATUS | 07-07-2016 |
20160376634 | HIGH-SELECTIVITY CONTACT ACTIVATION INHIBITOR BASED ON INFESTIN-4 - The present invention relates to medicine, and specifically to hematology, and can be used in particular for diagnostic and research purposes when determining coagulation characteristics of blood and its components, and also in biotechnology and fundamental biological research. | 12-29-2016 |
20170234853 | METHOD FOR DETERMINING THE STRUCTURAL PROFILE OF A FIBRIN CLOT REFLECTING THE STABILITY THEREOF, IN ORDER TO PREDICT THE RISK OF BLEEDING, THROMBOSIS OR RETHROMBOSIS | 08-17-2017 |
20170234895 | Two Component "Mix and Use" Liquid Thromboplastin Reagent, Methods of Making, and Methods of Use Thereof | 08-17-2017 |
20220137075 | LOW-VOLUME COAGULATION ASSAY - Compositions and methods for measuring coagulation parameters using very small volumes of blood are provided. Advantageously, the methods described herein can be performed from a single drop of blood (about 20 μL) while generally leaving enough sample to perform other measurements, optionally in a multiplexed format. The methods and devices do not require a skilled operator and can be performed at the point of service, which can be an important feature for managing blood coagulation disorders and treatments thereof. | 05-05-2022 |